OBJECTIVES: To assess the role of @entity2871 A2 and of @entity2178 in @entity1 with primary @entity2407 . DESIGN: After an eight-day run-in period, the @entity1 were enrolled in a single-blind, cross-over, study. SETTING: @entity1 were examined at the Ambulatory for Microcirculatory Diseases of the Clinic of Internal Medicine, University Hospital, Verona. SUBJECTS: Fifteen subjects affected by primary @entity2407 were included. MAIN OUTCOME MEASURES: A piezoelectric plethysmography to evaluate the distensibility of the digital arteries as the ratio between peak time (PT) and total time (TT), and an oscillometric blood pressure recorder were used after the run-in period, and after a two-week course of @entity37523 (300 mg b.i.d., i.e. two times daily) or @entity9886 (12.5 mg once daily) with an interval of a week of placebo between the active treatments. The tests were performed after every treatment in basal condition and during mental stress. The @entity1 reported in a diary the number and the severity (from 0 to 4 +) of the vasospastic crises. RESULTS: The change in TP/TT ratio appeared statistically significant only after @entity9886 treatment, both in basal condition and during mathematical stress. Both pharmacological treatments, with respect to placebo, showed an improvement of the scores, derived from the number and severity of @entity2142 , but only the therapy with @entity9886 determined a statistically significant improvement. CONCLUSIONS: The inhibition of the type 1 receptor for @entity2178 seems highly effective in the reduction of the vasospastic crises in the subjects with primary @entity2407 . According to our experience, @entity9886 could be used more extensively in the treatment of these @entity1 besides arterial @entity101 .

The effects of thromboxane A2 inhibition ( @entity37523 ) and XXXX receptor blockade ( @entity9886 ) in primary @entity2407 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2871 :: ('CHEBI:26995', 'Chemical') :: ['thromboxane'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity2178 :: ('183', 'Gene') :: ['angiotensin II'] @entity2407 :: ('MESH:D011928', 'Disease') :: ["Raynaud's phenomenon"] @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan'] @entity37523 :: ('MESH:C011581', 'Chemical') :: ['picotamide'] @entity2142 :: ('MESH:D006461', 'Disease') :: ['vasospastic attacks']
@entity2178 :: (183,Gene) :: ['angiotensin II']
